personalized medicine
Cancer Research UK, Guardant Health Ink Research, Data Sharing Partnership
The collaboration aims to help accelerate the discovery and development of cancer drugs and diagnostics through ongoing and potentially new clinical trials.
Burning Rock, Boehringer Ingelheim Ink Master Service Agreement for Oncology Companion Diagnostics
The companies will focus initially on Boehringer Ingelheim's MDM2-p53 antagonist, brigimadlin, now being studied in a new Phase II trial in China.
Genomic Profiling Aids Patients With Cancers of Unknown Primary in Trial, Though Benefit is Limited
In the CUPISCO trial, molecularly guided treatment reduced the risk of progression or death by 28 percent compared to patients receiving chemotherapy.
BostonGene, Exigent Research Ink Trial Agreement for Study of Comprehensive Cancer Sequencing
Using patient tumor samples from participating Exigent sites, BostonGene aims to validate its exome and RNA sequencing assay in a real-world setting.
Precede Biosciences Debuts Chromatin-Based Liquid Biopsy Platform Backed by New Data at ESMO
Premium
The firm has begun working with pharma, using its technology to identify and monitor transcriptionally regulated drug targets. It is also eyeing multiple clinical diagnostic applications.